secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arbutus Biopharma Corp (ABUS)
CIK:        0001447028
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001171843-26-001299
Event type: litigation
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arbutus/Genevant settle Moderna LNP patent litigation for $2.25B; $950M upfront due July 2026
--------------------------------------------------------------------------------

- Moderna to pay $950M upfront by July 8, 2026, plus $1.3B contingent on affirming rejection of Section 1498 defense.
- Arbutus receives 20% of proceeds after litigation costs under its Genevant license; total potential $2.25B.
- Arbutus evaluating a return of capital to shareholders in Q3 2026, tied to the upfront payment.
- Settlement includes judgment of infringement and no invalidity on four patents; global license for SM-102 LNP mRNA vaccines.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/0001171843-26-001299-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1447028/000117184326001299/f8k_030326.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-001299

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer